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ABSTRACT Ewing sarcoma is the second-most-common bone cancer in children. Driven by 
an oncogenic chromosomal translocation that results in the expression of an aberrant tran-
scription factor, EWS/FLI, the disease is typically aggressive and micrometastatic upon pre-
sentation. Silencing of EWS/FLI in patient-derived tumor cells results in the altered expres-
sion of hundreds to thousands of genes and is accompanied by dramatic morphological 
changes in cytoarchitecture and adhesion. Genes encoding focal adhesion, extracellular ma-
trix, and actin regulatory proteins are dominant targets of EWS/FLI-mediated transcrip-
tional repression. Reexpression of genes encoding just two of these proteins, zyxin and α5 
integrin, is sufficient to restore cell adhesion and actin cytoskeletal integrity comparable to 
what is observed when the EWS/FLI oncogene expression is compromised. Using an ortho-
topic xenograft model, we show that EWS/FLI-induced repression of α5 integrin and zyxin 
expression promotes tumor progression by supporting anchorage-independent cell growth. 
This selective advantage is paired with a tradeoff in which metastatic lung colonization is 
compromised.
INTRODUCTION
Ewing sarcoma is a round-cell malignant neoplasm of the bone 
that typically affects adolescents and young adults. It usually de-
velops in the diaphysis or metaphysis of long bones, most com-
monly in the femur, tibia, and humerus (Kimber et al., 1998; 
Spraker et al., 2012). Ewing sarcoma is an aggressive cancer that 
grows rapidly and metastasizes to lungs and bones (Karosas, 
2010). Treatment of apparently localized primary tumors involves 
chemotherapy and surgery and/or radiation therapy. Despite 
these interventions, many patients relapse even after definitive 
local control of the primary tumor, illustrating the fact that most 
patients have occult disseminated disease upon presentation 
(McAllister and Lessnick, 2005; Spraker et al., 2012). Patients with 
metastatic or recurrent disease face poor prognosis, with <15% 
5-yr survival rate. Knowledge of the molecular mechanisms that 
determine Ewing sarcoma cell behavior will be crucial in under-
standing disease progression and ultimately intervening with tar-
geted treatment.
Ewing sarcoma is caused by a reciprocal chromosomal transloca-
tion involving a portion of the EWSR1 gene on chromosome 22 and 
genes encoding members of the ETS family of transcription factors, 
most commonly FLI1, which maps to chromosome 11 (Turc-Carel 
et al., 1988; Delattre et al., 1992; Sankar and Lessnick, 2011). 
In ∼85% of cases, a t(11;22)(q24;q12) translocation results in the 
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RESULTS
EWS/FLI expression compromises the cytoskeleton of Ewing 
sarcoma cells
The cell of origin that gives rise to Ewing sarcoma has not been 
definitively identified (Ewing, 1921; Cavazzana et al., 1987; Kovar, 
2005; Tirode et al., 2007; Jedlicka, 2010). Consequently, the ap-
proach of ectopic EWS/FLI expression as a way to model oncogene 
effect on cell behavior is fraught with difficulty, owing to the uncer-
tain effect of inappropriate cellular context (Braunreiter et al., 2006; 
Owen and Lessnick, 2006). To circumvent this challenge, we studied 
how the EWS/FLI oncoprotein influences cellular behavior by using 
an RNA interference (RNAi) approach to knock down EWS/FLI 
expression in patient-derived Ewing sarcoma cells (A673 and 
EWS502).
We used retrovirally encoded short hairpin RNA directed 
against EWS/FLI transcripts to knock down the expression of EWS/
FLI (EWS/FLI RNAi), with RNAi against luciferase serving as our 
control RNAi, and compared the resulting alterations in cellular 
behavior. We reported previously that knockdown of EWS/FLI ex-
pression in multiple human Ewing sarcoma cell lines resulted in 
dramatic effects on cell phenotype, including alterations in adhe-
sion and motility (Chaturvedi et al., 2012). In an effort to mimic the 
extracellular matrix context found within bone, the site of Ewing 
sarcoma genesis, we examined the behavior of cells plated on 
fibronectin, an extracellular matrix protein that is prominent in 
bone (Rodan and Rodan, 1997). As can be seen in Figure 1A, 
Ewing sarcoma cells displayed a profound cytoskeletal deficit 
when cultured on a fibronectin matrix. The A673 cells appeared 
small and poorly spread, with thin and short actin stress fibers. In 
contrast, when EWS/FLI expression was knocked down by RNAi, 
the Ewing sarcoma cells underwent a dramatic morphological 
transformation in which they exhibited pronounced adhesion and 
spreading to the fibronectin substratum and displayed robust actin 
stress fibers. These results illustrated the effect of EWS/FLI expres-
sion on adhesion and cytoarchitecture and prompted us to explore 
the mechanism by which EWS/FLI influences these phenotypic at-
tributes of Ewing sarcoma cells.
EWS/FLI targets gene expression of many adhesion-related 
genes
EWS/FLI is an oncogenic transcription factor that modulates the ex-
pression of hundreds to thousands of genes (Owen et al., 2008). To 
identify candidate targets of EWS/FLI that might influence adhesion 
and cytoarchitecture, we analyzed a previously published microarray 
analysis of EWS/FLI-regulated genes (Owen et al., 2008). Selection 
of genes whose expression was decreased at least 1.8-fold by EWS/
FLI revealed 222 genes that were down-regulated by EWS/FLI by 
this criterion. Kyoto Encyclopedia of Genes and Genomes (KEGG) 
analysis revealed that the top three classes of genes down-regulated 
by EWS/FLI were those encoding focal adhesion proteins, modula-
tors of extracellular matrix–receptor interactions, and regulators of 
the actin cytoskeleton (Table 1), consistent with the major cellular 
phenotypes we observed in Ewing sarcoma cells (Figure 1A; 
Chaturvedi et al., 2012). Inspection of the EWS/FLI down-regulated 
genes revealed that more than one-third would be expected to influ-
ence the actin cytoskeleton, cell–matrix communication, or cell ad-
hesion and migration based on their annotated functions (Supplemen-
tal Table S1). The largest single class of genes down-regulated by 
EWS/FLI expression encode focal adhesion proteins. Focal adhe-
sions are regions of the cell surface specialized for cell–matrix adhe-
sion and transmembrane communication, known to convey informa-
tion about extracellular matrix composition, as well as mechanical 
expression of a chimeric transcription factor in which a strong tran-
scription regulatory domain found in EWS is fused to a portion of FLI 
that includes a DNA-binding domain (Aurias et al., 1984; Delattre 
et al., 1992; Lessnick et al., 1995; May et al., 1993a). EWS/FLI acts as 
a master transcriptional regulator that modulates the expression of 
a large number of genes. Several up-regulated targets of EWS/FLI 
have been extensively studied, including NKX2.2, NR0B1, and 
Caveolin1 (Kinsey et al., 2006; Tirado et al., 2006; Owen et al., 
2008). Although predicted to aberrantly activate transcription, EWS/
FLI also causes repression of hundreds to thousands of genes 
(Kinsey et al., 2006; Smith et al., 2006; Owen et al., 2008). With a 
few exceptions (Mateo-Lozano et al., 2003; Herrero-Martin et al., 
2009; Borinstein et al., 2011), the down-regulated targets of EWS/
FLI have not been extensively characterized. However, recent work 
provides evidence that a key mode of oncogenic transformation by 
EWS/FLI involves repression of specific gene expression (Sankar 
et al., 2013a). Understanding the targets and effect of EWS/FLI-
dependent transcriptional repression is thus a key imperative in dis-
section of the pathogenesis of Ewing sarcoma.
Recent studies suggest that EWS/FLI is not only required for tu-
morigenesis (Smith et al., 2006), but it also modulates key cellular 
properties such as cell adhesion, motility, and invasion (Chaturvedi 
et al., 2012). For example, RNA interference–based knockdown of 
EWS/FLI expression in human Ewing sarcoma cells revealed that 
EWS/FLI promotes loss of cytoskeletal integrity as well as reduced 
tumor cell adhesion and spreading (Chaturvedi et al., 2012). The 
dramatic effect of the transforming oncogene EWS/FLI on cell archi-
tecture and adhesion could provide a mechanism to couple unregu-
lated cell growth to phenotypic changes that promote sarcoma me-
tastasis, perhaps explaining why Ewing sarcoma displays such early 
metastatic behavior. In theory, the aberrant regulation of adhesion 
genes by EWS/FLI could affect multiple stages of Ewing sarcoma 
metastasis: initial tumor cell release and dissemination, extravasa-
tion, and second-site adhesion/colonization.
Here we analyze the gene expression changes associated with 
knockdown of EWS/FLI expression in human Ewing sarcoma cells, 
with the goal of interrogating the mechanisms underlying the 
dramatic alterations in cytoskeleton and cell adhesion that ac-
company transformation by EWS/FLI. We find that the top three 
classes of genes that are repressed by EWS/FLI expression are 
categorized as genes related to structure or function of focal 
adhesions, extracellular matrix (ECM)–receptor interactions, and 
regulation of the actin cytoskeleton. By genetic reconstitution 
experiments, we identified zyxin and α5 integrin as two EWS/FLI 
target genes that, when reexpressed in Ewing sarcoma cells, are 
sufficient to induce a dramatic restoration of actin cytoarchitec-
ture and cell adhesion. We extend the results from cell biology 
studies into an experimental mouse model that effectively reca-
pitulates the clinical manifestations of Ewing sarcoma observed 
in patients, including rapid formation of osteolytic tumors and 
aggressive metastasis to lungs and other bones. Our results high-
light the importance of misregulation of adhesion and cytoskel-
etal regulation for Ewing sarcoma tumor phenotype. In addition, 
our findings suggest that misregulation of genes within tumors 
can alternately provide selective advantages or disadvantages, 
depending on the specific context. Our results illustrate that not 
all gene expression changes that are promoted by transforming 
oncogenes are advantageous for all aspects of a tumor’s life his-
tory, but instead that the changes may be enabling for one as-
pect, such as supporting anchorage-independent cell growth, 
even as they may compromise the ability of the tumor cells to 
establish colonies at second sites.
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by abrogating cell–matrix adhesion and 
the associated actin cytoskeleton.
Validating the microarray findings, 
Western immunoblot analysis comparing 
the protein complements in control and 
EWS/FLI-knockdown cells revealed that 
both zyxin and α5 integrin are down-regu-
lated by EWS/FLI expression (Figure 1B). 
Evidence that the RNAi was effective in ab-
rogating EWS/FLI expression is shown in 
Figure 1B, in which FLI-1 antibody detects 
reduced EWS/FLI fusion protein. Tubulin ex-
pression serves as a surrogate for cell num-
ber and controls for equivalent sample load-
ing in this experiment.
Reexpression of zyxin and α5 integrin 
in Ewing sarcoma cells influences the 
actin cytoskeleton, cell adhesion, 
and spreading
To study the effect of reduced expression of 
zyxin and α5 integrin in Ewing sarcoma, we 
reexpressed these down-regulated targets 
in patient-derived Ewing sarcoma cells us-
ing retrovirus to program the cells to express 
these cDNAs of interest. As can be seen in 
Figure 1C, by Western immunoblot analysis, 
we observe increases in zyxin and/or α5 in-
tegrin expression in the reprogrammed 
cells. Expression of these proteins does not 
detectably alter the levels of EWS/FLI in the 
cells, as detected with anti-FLI1 antibody.
Although EWS/FLI affects the expression 
of hundreds to thousands of genes, the re-
expression of just one or two of these, zyxin 
and/or α5 integrin, in the Ewing sarcoma 
cells resulted in dramatic phenotypic altera-
tions in the cells. Of importance, the indi-
vidual expression of zyxin and α5 integrin 
induced distinct alterations in morphology and cytoarchitecture of 
the Ewing sarcoma cells. Compared to the parental A673 cells in-
fected with the empty retroviral vector, which were poorly spread 
and exhibited only rudimentary stress fibers (Figure 1D), Ewing sar-
coma cells programmed to express zyxin displayed a profound 
elaboration of actin stress fibers, with an increase in cell spreading 
as well (Figure 1E). Expression of α5 integrin alone appeared to im-
prove cell spreading without resulting in enhancement of actin cy-
toskeletal arrays (Figure 1F). When these proteins were coexpressed, 
the Ewing sarcoma cells were marked by both well-formed actin 
stress fibers and enhanced cell spreading (Figure 1G). Expression of 
zyxin and/or α5 integrin in a second Ewing sarcoma cell line, EWS502 
cells, also resulted in a more organized actin cytoskeleton with en-
hanced cell spreading (Supplemental Figure S1).
Higher magnification and quantitative analysis of these initial 
findings confirmed the significant and unique effects of zyxin and α5 
integrin on Ewing sarcoma cell morphology and cytoarchitecture 
(Figure 2). The cells were double labeled with phalloidin to visualize 
filamentous actin (Figure 2, A–D) and anti-paxillin antibody to mark 
focal adhesions (Figure 2, E–H). The size (Figure 2I) and number 
(Figure 2J) of focal adhesions were quantitated for each experimen-
tal condition. Knockdown of EWS/FLI expression in Ewing sarcoma 
cells resulted in a statistically significant increase in the average focal 
stress to the cell interior. Focal adhesions are themselves complex 
multicomponent structures, with >100 known protein constituents 
(Zaidel-Bar et al., 2007; Geiger and Yamada, 2011).
From the list of genes that are down-regulated by EWS/FLI, we 
selected the genes encoding zyxin and α5 integrin for further 
study because of their known influence on cytoskeleton and cell–
matrix interactions. Zyxin is an evolutionarily conserved regulator 
of the actin cytoskeleton that is required for maintenance and re-
pair of actin stress fibers (Yoshigi et al., 2005; Smith et al., 2010; 
Hoffman et al., 2012). Zyxin was previously shown to be down-
regulated when EWS/FLI is expressed in 3T3 fibroblasts, illustrat-
ing that EWS/FLI repression of zyxin expression occurs in multiple 
cellular contexts (Amsellem et al., 2005). Integrins are transmem-
brane αβ heterodimeric receptors for extracellular matrix that are 
critical for cell–substratum adhesion, as well as for stress fiber an-
chorage and integrity (Lotz et al., 2000; Hynes, 2002; Campbell 
and Humphries, 2011). The α5 integrin is a known modulator of 
cell adhesion, migration, and cell–matrix communication that di-
merizes with β1 integrin subunit to confer adhesion to fibronectin 
(Mostafavi-Pour et al., 2003; Margadant et al., 2011; Gupton et al., 
2012; Nagae et al., 2012). Fibronectin expression is also reduced 
in EWS/FLI-transformed cells (Supplemental Table S1), consistent 
with the proposal that the EWS/FLI oncogene acts, at least in part, 
FIGURE 1: EWS/FLI-dependent changes in the actin cytoskeleton and contributions of 
cytoskeletal regulators. (A) Widefield fluorescence images of A673 Ewing sarcoma cells stained 
with phalloidin to visualize the actin filament network. A673 cells with EWS/FLI RNAi had robust 
actin cytoskeletons and were more spread than A673 cells with control RNAi. Scale bar, 20 μm. 
(B) Western immunoblot of parent Ewing sarcoma A673 cells (lane 1), A673 cells with control 
RNAi (lane 2), or EWS/FLI RNAi (lane 3) were probed with antibodies for FLI-1, zyxin, α5 
integrin, and tubulin (loading control). EWS/FLI knockdown resulted in increased zyxin and α5 
integrin protein. (C) Western immunoblot of Ewing sarcoma cells engineered to express empty 
vector, zyxin, α5 integrin, or both α5 integrin and zyxin were probed with antibodies for FLI-1, 
zyxin, α5 integrin, and tubulin (loading control). Independent expression of zyxin or α5 integrin 
above the endogenous levels in A673 cells did not affect the level of the other protein. 
(D–G) Widefield fluorescence images of phalloidin-stained A673 cells engineered to express 
empty vector (D), zyxin (E), α5 integrin (F), or both α5 integrin and zyxin (G) suggest increased 
actin cytoskeleton and cell spreading in cells that reexpress these proteins.
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adhesion size from 1.3 to 1.8 μm2 (Figure 2I). Reexpression of either 
zyxin, α5 integrin, or both zyxin and α5 integrin restored the size of 
paxillin-rich focal adhesions to a level that is not statistically different 
from what is observed when EWS/FLI is knocked down in Ewing 
sarcoma cells by RNAi (Figure 2I).
Ewing sarcoma cells or those with control RNAi displayed fewer 
focal adhesions (∼50/cell) than cells in which EWS/FLI expression 
was knocked down, which exhibited an average of 177 focal adhe-
sions/cell (Figure 2J). Expression of zyxin and/or α5 integrin in 
Ewing sarcoma cells resulted in a statistically significant increase of 
focal adhesion number (Figure 2J). Of interest, however, zyxin ex-
pression had a more profound effect on focal adhesion number than 
did expression of α5 integrin. For example, expression of α5 integ-
rin led to moderate increase in number of focal adhesions from an 
average of 50 to 70 per cell (Figure 2J). However, expression of zyxin 
alone or with α5 integrin led to dramatic increase in the focal adhe-
sion number to >150 focal adhesions/cell (Figure 2J), highlighting 
the differential effect of zyxin and α5 integrin on focal adhesion 
number.
Given the established link between focal adhesion develop-
ment and cell spreading (Smilenov et al., 1999; Salsmann et al., 
2006), the increased focal adhesion size and number observed 
upon reexpression of zyxin and/or α5 integrin was consistent with 
low-magnification analysis, which suggested that reexpression of 
either zyxin or α5 integrin enhanced cell spreading. To examine 
this possibility quantitatively, we measured the areas of phalloidin-
stained cells (e.g., cells such as those represented in Figure 2, 
A–D). Expression of zyxin and/or α5 integrin resulted in statisti-
cally significant increase in cell spreading, illustrated by increased 
average cell area (Figure 2K). Measured cell area increased from 
950 μm2 for A673 Ewing sarcoma cells harboring empty vector to 
>1500 μm2 for cells expressing one or more of the adhesion pro-
teins (Figure 2K). Consistent with the findings with A673 cells, ex-
pression of zyxin and α5 integrin, alone or in combination, was 
also sufficient to enhance cell area of EWS502 Ewing sarcoma 
cells, and enhanced actin cytoskeletons and focal adhesions were 
prominently induced by expression of zyxin (Supplemental Figure 
S1). Reexpression of zyxin induced a more robust spreading 
response than what occurred with reexpression of α5 integrin, 
although both displayed more extensive cell spreading than the 
parental A673 Ewing sarcoma cells. Of interest, Ewing sarcoma 
cells programmed to knock down EWS/FLI displayed an average 
cell area (∼2200 μm2) that was indistinguishable from the average 
area of cells expressing either zyxin alone or in combination with 
α5 integrin, illustrating that reexpression of zyxin is sufficient to 
fully rescue the cell spreading deficit observed in Ewing sarcoma 
cells.
The increased cell spreading and focal adhesion assembly was 
associated with enhanced adhesion, as measured in a quantita-
tive, short–time course cell adhesion assay (Figure 2L). In this 2-h 
adhesion assay, the cells were allowed to adhere to an uncoated 
plastic tissue culture dish. Knockdown of EWS/FLI expression re-
sulted in a statistically significant increase in cell adhesion (Figure 
2L). Reexpression of α5 integrin alone or with zyxin enhanced cel-
lular adhesion comparable to cells in which EWS/FLI expression 
was knocked down by RNAi. Although Ewing sarcoma cells reex-
pressing zyxin also displayed increased cell adhesion by this as-
say, the effect was not as dramatic as in the case of α5 integrin 
expression (Figure 2L). The profound yet differential capacities of 
zyxin and α5 integrin to restore cell spreading, actin cytoskeleton, 
and focal adhesion number are summarized schematically in 
Figure 2M.
KEGG pathway
Number 
of genes
Gene 
set z-score
1 Focal adhesion 24 190 8.5
2 ECM–receptor interaction 14 80 8.1
3 Regulation of actin  
cytoskeleton
13 187 3.6
4 Amoebiasis 12 100 5.7
5 Protein processing in  
endoplasmic reticulum
12 144 4.2
6 Lysosome 10 109 4.1
7 Phagosome 9 139 2.7
8 Arrhythmogenic right ventric-
ular cardiomyopathy (ARVC)
8 68 4.6
9 Cell adhesion molecules 
(CAMs)
8 116 2.8
10 Antigen processing and pre-
sentation
7 61 4.2
11 Natural killer cell–mediated 
cytotoxicity
7 117 2.2
12 Protein digestion and  
absorption
7 70 3.7
13 Toxoplasmosis 7 118 2.1
14 Viral myocarditis 7 65 4.0
15 Adherens junction 6 71 3.0
16 Bacterial invasion of  
epithelial cells
6 64 3.3
17 Dilated cardiomyopathy 6 82 2.5
18 Hypertrophic cardiomyopathy 
(HCM)
6 79 2.7
19 Small-cell lung cancer 6 83 2.5
20 Complement and coagulation 
cascades
5 67 2.4
21 Prion diseases 5 34 4.3
22 Shigellosis 5 55 2.9
23 Allograft rejection 4 32 3.4
24 Amino sugar and nucleotide 
sugar metabolism
4 42 2.7
25 Autoimmune thyroid disease 4 48 2.4
26 Bladder cancer 4 41 2.8
27 Graft-versus-host disease 4 33 3.3
28 NOD-like receptor signaling 
pathway
4 54 2.1
29 Type I diabetes mellitus 4 37 3.0
30 Glycosaminoglycan biosyn-
thesis–chondroitin sulfate
2 16 2.4
31 Glycosaminoglycan  
degradation
2 18 2.2
KEGG pathway groups of genes that are down-regulated at least 1.8-fold by 
EWS/FLI. The top three categories modulated by EWS/FLI are genes encoding 
focal adhesion–related proteins, ECM and receptor interaction proteins, and 
regulators of the actin cytoskeleton. The KEGG analysis therefore suggests the 
importance of cell adhesion and cytoskeletal pathways and components for 
EWS/FLI-dependent changes in Ewing sarcoma.
TABLE 1: Categories of down-regulated target genes of EWS/FLI 
oncoprotein.
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Intratibial orthotopic mouse model for 
Ewing sarcoma recapitulates features 
of the human disease
The ultimate goal of our studies was to un-
derstand the critical cellular mechanisms 
that are compromised in EWS/FLI-trans-
formed cells and decipher the consequences 
of these alterations for tumor biology. To 
test whether increasing cellular adhesion by 
the reexpression of zyxin and α5 integrin in 
Ewing sarcoma cells would affect tumor cell 
FIGURE 2: Zyxin and α5 integrin contribute 
to the actin cytoskeleton, focal adhesions, 
cell spreading, and cell adhesion in Ewing 
sarcoma cells. (A–H) A673 cells engineered to 
express empty vector (A, E), zyxin (B, F), α5 
integrin (C, G), or both α5 integrin and zyxin 
(D, H) were stained for actin filaments 
(phalloidin, A–D) and focal adhesions (paxillin, 
E–H), followed by immunofluorescence 
microscopy. Control A673 cells were small 
and round, with minimal actin stress fibers 
and few focal adhesions. Cells that express 
zyxin, α5 integrin, or both α5 integrin and 
zyxin were well spread, with prominent focal 
adhesions. Focal adhesion size (I) and number 
per cell (J) were quantitated for at least 25 
cells (each condition) and compared between 
control and EWS/FLI RNAi cells and cells that 
express zyxin, α5 integrin, or both α5 
integrin and zyxin. (K) Total cell area was 
measured in at least 35 phalloidin-stained 
cells with either RNAi (control and EWS/FLI) 
or with expression of zyxin, α5 integrin, or 
both α5 integrin plus zyxin. Cell spreading 
and area increased with EWS/FLI knockdown 
and with expression of zyxin and α5 integrin. 
(L) Cell adhesion was evaluated by plating 
cells for 2 h, followed by colorimetric 
detection. Data are graphed as mean with 
SEM (six wells each cell type). Cells with 
control RNAi or empty vector adhered less 
than cells with EWS/FLI RNAi or cells that 
express zyxin, α5 integrin, or both α5 
integrin and zyxin. (M) Model of Ewing 
sarcoma cell phenotypes. The actin 
cytoskeleton and focal adhesions, cell 
spreading, and cell area are changed by 
these proteins in unique and distinct ways. 
EWS/FLI expression compromises Ewing 
sarcoma cell adhesion by influencing actin 
cytoskeleton, cell morphology, and 
spreading, perhaps due to the down-
regulation of cell adhesion proteins in general 
and of zyxin and α5 integrin in particular. For 
I–K, data are graphed as box-and-whisker 
plot (median with 25% quartile above and 
below in the box, and whiskers as minimum 
to maximum), with the individual data points 
included as scatter plot. Bars identify the 
data sets compared in parametric unpaired t 
tests. ***p < 0.001; other comparisons were 
not statistically different.
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behavior in vivo, we first established an or-
thotopic xenograft model in our lab that 
faithfully replicates key aspects of Ewing sar-
coma behavior. Xenograft models of Ewing 
sarcoma cells implanted at nonorthotopic 
sites in mice (e.g., subcutaneous flank injec-
tions in nude mice) are useful for evaluating 
tumor growth response to cell type or drug 
treatment (Smith et al., 2006; Houghton 
et al., 2010; Sankar et al., 2013b; Ambati 
et al., 2014), but such models do not ac-
count for the complexity of the bone mi-
croenvironment for either primary tumor 
establishment or metastasis to secondary 
sites. Studies in which Ewing sarcoma cells 
have been introduced directly into mouse 
tibias have enabled examination of tumor-
induced osteolytic bone destruction and 
dissemination from the orthotopic site (Guan 
et al., 2008; Hauer et al., 2013). Luciferase 
tagging of Ewing sarcoma cells before or-
thotopic injection enables in vivo biolumi-
nescence imaging to track tumor cell loca-
tion (Wang et al., 2009). Building on these 
prior approaches, we injected luciferase-ex-
pressing A673 Ewing sarcoma cells that 
were suspended in Matrigel into tibias of 
immunodeficient mice. After tumor cell in-
troduction, we systematically monitored tu-
mor growth and progression, osteolysis, and 
metastasis (Figure 3A).
Under our experimental conditions, tu-
mors grew rapidly and were highly oste-
olytic. Most of the mice (14 of 15) formed 
tumors in the injected tibia that were pal-
pable and measurable by in vivo luciferase 
imaging, and we observed aggressive 
growth of these tumors (Figure 3B). Tibial 
radiographs revealed extensive osteolysis 
(Figure 3C), a common characteristic of Ew-
ing sarcoma progression in human patients. 
Radiographic analysis revealed that 85% of 
mice displayed cortical bone destruction 
and massive bone loss by week 4, warrant-
ing a classification of grade 3 or 4 osteolysis 
(Figure 3D).
FIGURE 3: Intratibial orthotopic mouse model for Ewing sarcoma recapitulates features of the 
human disease. (A) Schematic diagram of the orthotopic mouse model, in which A673 Ewing 
sarcoma cells engineered to express luciferase were injected into the tibia, then monitored 
weekly for 4 wk for tumor growth, osteolysis, and metastasis, followed by ex vivo analysis and 
histopathology. (B) Tibial tumor growth and proliferation of Ewing sarcoma cells were measured 
by in vivo luciferase bioluminescence imaging. Data are graphed as mean with SEM, n = 5 mice. 
(C) Osteolysis (white arrows indicate regions of bone loss) increased compared with the same 
mouse tibia at week 1. (D) Qualitative analysis of mouse radiographs by an independent analyst 
revealed ∼85% of mice had high-grade osteolysis (grade 3 or 4) in the injected tibias. 
(E) Histopathological analysis of tibial tumors showed highly invasive tumor in the tibia (1, 5×) 
and closer examination (2, 20×; and 3, 400×) 
revealed the presence of typical small, round, 
blue Ewing sarcoma cells. Membranous 
staining for Ewing sarcoma marker CD99 
(brown staining in 4) confirmed Ewing 
sarcoma cells in the tibial tumor, and CD99 
staining was negative in a normal tibia (5). 
(F) Mouse lung with metastatic lesions 
sectioned and stained by H&E (1, 2) also 
contained small, round, blue cells typical of 
Ewing sarcoma, and the lung was positive for 
Ewing sarcoma marker CD99 (brown staining 
in 3) and negative for CD99 in a normal lung 
(4). (G) Representative ex vivo luciferase 
imaging to evaluate metastasis in lungs and 
bones at harvest.
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Ewing sarcoma is distinguished by its small, round, blue cell mor-
phology when tissue biopsy sections are stained with hematoxylin 
and eosin (H&E), as well as by distinct membrane labeling with anti-
bodies directed against CD99, a transmembrane glycoprotein that 
serves as a diagnostic biomarker for Ewing sarcoma (Ambros et al., 
1991; Fellinger et al., 1991; Perlman et al., 1994). Consistent with 
features observed in clinical samples, the histological presentation 
and positive CD99 staining of Ewing sarcoma cells in the mouse 
model were indistinguishable from what is observed in human pa-
tient samples (Figure 3E), illustrating preservation of key morpho-
logical properties of the human tumor cells in the context of the 
murine host. The CD99 staining further confirmed the human origin 
of the cells, since mice do not express this marker.
In patients, Ewing sarcoma arises in bone and has a propensity 
to metastasize to lung and other bones (Arndt and Crist, 1999; 
Spraker et al., 2012). This metastatic profile is also preserved in our 
orthotopic xenograft model (Figure 3, F and G). In vivo imaging of 
the luciferase-tagged Ewing sarcoma cells in the mice revealed that 
half exhibited positive signal in the chest area, suggesting potential 
metastasis to the lungs. On dissection and histopathological analy-
sis, lungs that were luciferase positive exhibited small, round, blue 
cells by H&E staining and positive anti-CD99 labeling, confirming 
the presence of metastatic Ewing sarcoma cells (Figure 3F). Lu-
ciferase imaging of the mouse carcass revealed metastasis to other 
sites, such as the left tibia or upper limb and occasionally ribs and 
spine (Figure 3G). Establishment of a robust mouse model system 
for Ewing sarcoma that recapitulates key clinical features of the hu-
man disease set the stage for studies of the effect of EWS/FLI de-
pendent gene regulation in vivo.
EWS/FLI-dependent repression of zyxin and α5 integrin 
expression enhances anchorage-independent growth of 
Ewing sarcoma cells
To probe the effect of EWS/FLI-dependent repression of zyxin and 
α5 integrin expression, we introduced Ewing sarcoma cells that 
were engineered to reexpress one or both of these proteins into 
recipient mice via intratibial injection, as described, and compared 
the growth of the resulting primary tumors with those derived from 
parental A673 cells. In all four groups (A673 parental, zyxin reex-
pression, α5 integrin reexpression, and zyxin plus α5 integrin reex-
pression), 90–100% of the mice formed luciferase-positive tumors 
within 4 wk after intratibial injection (Figure 4A). Histological analysis 
of tissue sections taken at week 4 revealed that all of the tumors 
exhibit small, round, blue cell morphology characteristic of Ewing 
sarcoma and were CD99 positive by immunohistochemistry (Sup-
plemental Figure S2). Light microscopic examination revealed no 
differences among the four tumor groups. Similarly, significant oste-
olysis (>grade 3) was evident in radiographs of the affected tibias at 
4 wk for tumors derived from all four cell variants (Figure 4B).
Although all four tumor cell variants formed palpable tumors and 
osteolytic lesions, in vivo luciferase-based imaging of tumors de-
rived from A673 cells coexpressing zyxin and α5 integrin revealed 
slower tumor growth than tumors derived from either parental A673 
cells or cells expressing just one of the transgenes (Figure 4C). This 
observation suggests that EWS/FLI-mediated down-regulation of 
zyxin and α5 integrin synergistically facilitates tumor growth.
The reduction in primary tumor growth by Ewing sarcoma cells 
that expressed both zyxin and α5 integrin raised the possibility that 
reexpression of these two focal adhesion proteins might affect cell 
proliferation rate. To test this possibility directly, we measured cell 
growth in culture (Figure 4D). The three reexpression lines displayed 
growth curves that were indistinguishable from that of the parental 
FIGURE 4: Zyxin and α5 integrin coexpression in Ewing sarcoma cells 
reduce tumor growth, whereas osteolytic degradation of bone 
persists. (A) In vivo luciferase imaging of mice 4 wk after intratibial 
injections with Ewing sarcoma A673 cells engineered to express 
empty vector, zyxin, α5 integrin, or both α5 integrin and zyxin. Every 
cell type was capable of inducing tibial tumors detectable by 
bioluminescence imaging. (B) Radiographs of tibias 4 wk after 
injections with cells that express empty vector, zyxin, α5 integrin, or 
both α5 integrin and zyxin revealed high-grade osteolysis (white 
arrows) regardless of which cell type was injected. (C) In vivo 
luciferase imaging of tibial tumors for 4 wk. Bioluminescence signals 
restricted to the tibial tumor region were quantitated (photons/
second) and graphed over time as mean with SEM. *p < 0.05 for 
unpaired t test between empty vector group (n = 15 mice) and α5 
integrin plus zyxin group (n = 10 mice). Expression of α5 integrin plus 
zyxin in Ewing sarcoma cells inhibited the tumor growth compared 
with the other groups. (D) 3T5 cell growth assay of A673 Ewing 
sarcoma cells with empty vector, zyxin, α5 integrin, or both α5 
integrin and zyxin did not detect a difference in growth and 
proliferation in culture. Data from a single experiment are shown, 
representative of three sets of cell growth assays. (E) Soft-agar 
transformation and colony formation of cells with empty vector, zyxin, 
or α5 integrin alone were not different. However, colony formation in 
soft agar was inhibited in A673 cells that expressed both α5 integrin 
and zyxin. Graph is shown as mean with SEM, and ***p <0.001 in 
unpaired Student’s t test between empty vector and α5 integrin plus 
zyxin data sets.
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ments, we used a competitive lung colonization assay in which we 
differentially labeled Ewing sarcoma cells harboring empty vector 
using the red lipophilic dye DiI and cells reexpressing zyxin and/or 
α5 integrin green using the lipophilic dye DiO. An equal mix of 
control cells and cells reexpressing zyxin and/or α5 integrin was in-
troduced into the bloodstream of immunodeficient mice via tail-vein 
injection (Padua et al., 2008; Chaturvedi et al., 2012). Lungs were 
harvested 24 h postinjection and cryosectioned. We scanned 15 
such representative sections measuring 4 mm2 in area for the pres-
ence of fluorescently labeled red or green cells adhering to lung 
parenchyma, using confocal microscopy (Figure 6, A–C). Some tu-
mor cells were present within capillaries, whereas others appeared 
to have extravasated out of the capillary bed. Although Ewing sar-
coma cells adhered to the lung tissue, we observed an elevated 
number of tumor cells in the lungs when zyxin and/or α5 integrin 
were reexpressed. This was clearly indicated by increased number 
of green cell colonies in the lung parenchyma sections compared 
with red cell colonies (Figure 6). Expression of zyxin (Figure 6A), α5 
integrin (Figure 6B), or both zyxin and α5 integrin (Figure 6C) signifi-
cantly increased the number of tumor cells resident in the lung 
(Figure 6D). As discussed later, although an increased tumor cell 
burden was clearly evident in the lungs when the tumor cells were 
programmed to express zyxin and/or α5 integrin, it is not clear 
whether this is due to increased dwell time within the capillaries, 
improved adhesion to target lung parenchyma, or both.
DISCUSSION
Nearly all cases of Ewing sarcoma harbor the t(11;22) chromosomal 
translocation and are aggressive and micrometastatic at presenta-
tion. However very little is understood about how EWS/FLI expres-
sion, which represses many more genes than it activates, affects 
complex cell behaviors that dictate Ewing sarcoma tumor progres-
sion and metastasis (May et al., 1993b; Smith et al., 2006; Owen 
et al., 2008). Our recent work (Chaturvedi et al., 2012) established 
that EWS/FLI expression triggers a profound loss of cell adhesion 
and disturbance of actin cytoskeletal architecture. To dissect the 
mechanism by which EWS/FLI induces these tumor cell properties, 
we used patient-derived Ewing sarcoma cell lines to identify the 
misregulated genes responsible for the tumor phenotypes. This 
study links specific genes that are misregulated by EWS/FLI expres-
sion to the phenotypic alterations in cytoskeletal integrity and adhe-
siveness observed in patient-derived Ewing sarcoma cells.
Consistent with our findings that knockdown of EWS/FLI expres-
sion in Ewing sarcoma cells results in a dramatic alteration in cell 
adhesion and cytoarchitecture, analysis of the gene expression sig-
nature of EWS/FLI using a previously published microarray (Owen 
et al., 2008) revealed that the most prominent down-regulated tar-
gets of EWS/FLI were focal adhesion proteins, ECM–receptor pro-
teins, and regulators of the actin cytoskeleton. This collection of 
EWS/FLI-repressed genes could play a critical role in modulating 
tumor cell adhesion, cell spreading, and interaction of tumor cells 
with their environment to influence tumor progression and metasta-
sis. Here we dissected the effect of two such EWS/FLI down-regu-
lated targets, zyxin (a focal adhesion protein) and α5 integrin, which, 
along with the β1 integrin subunit, forms the receptor for binding 
fibronectin, a prominent bone matrix component. We reexpressed 
these proteins in patient-derived Ewing sarcoma cells either alone 
or in combination with each other to identify the unique and distinct 
contributions of zyxin and α5 integrin in Ewing sarcoma biology, 
both in vitro and in vivo. The reexpression of α5 integrin and zyxin 
within Ewing sarcoma cells results in a striking morphological change 
in the sarcoma cells that is essentially indistinguishable from what 
A673 Ewing sarcoma cells, indicating that anchorage-dependent 
cell proliferation was not detectably influenced by altering zyxin or 
α5 integrin levels. In striking contrast, simultaneous reexpression of 
zyxin and α5 integrin in A673 cells results in ∼40% reduction in the 
number of cell colonies in a soft-agar transformation assay, whereas 
neither individual protein had a statistically significant effect (Figure 
4E). Consistent with our quantitative analysis of viable tumor cells by 
in vivo luciferase monitoring in Figure 4C, coexpression of zyxin and 
α5 integrin synergistically retards cell growth in soft agar. Thus the 
reduction in zyxin and α5 integrin that occurs in response to EWS/
FLI expression appears to enhance the cells’ capacity to grow under 
anchorage-independent conditions.
EWS/FLI-dependent repression of α5 integrin expression 
abrogates metastatic lung colonization
Because of the effect of cell adhesion in establishing metastatic po-
tential (Arjonen et al., 2011; Patel et al., 2011), it was of interest to 
evaluate whether repression of zyxin and/or α5 integrin expression 
influences this process. The tibial injection model we developed, in 
which metastasis of Ewing sarcoma cells follows the pattern of sites 
observed clinically in patients, enabled us to probe the roles of zyxin 
and/or α5 integrin in the spatial and temporal regulation of meta-
stasis. A673 parental Ewing sarcoma cells or cells engineered to re-
express zyxin and/or α5 integrin were introduced into recipient mice 
by intratibial injection and were followed by weekly in vivo luciferase 
imaging for 4 wk to evaluate the rate at which metastasis (positive 
chest signal) developed for each A673 sarcoma cell variant (Figure 
5A). By 14 d after intratibial injection, intravital imaging revealed evi-
dence of tumor burden beyond the initial site of tumor cell injection 
in all sample groups; however differential levels of metastasis were 
already evident for the different molecular variants of A673 Ewing 
sarcoma cells. A higher percentage of the mice injected with Ewing 
sarcoma cells that reexpressed α5 integrin alone or in concert with 
zyxin displayed positive luciferase signal in the chest earlier than 
mice injected with Ewing sarcoma cells harboring empty vector 
(Figure 5A). By week 4 (Figure 5B), metastasis was evident by in vivo 
imaging in 90–100% of the animals injected with A673 sarcoma cells 
that reexpressed α5 integrin alone or with zyxin. In contrast, only 
56% of animals injected with A673 cells programmed to reexpress 
zyxin and 47% of animals injected with parental A673 cells exhibited 
chest signal at week 4 (Figure 5B).
We further examined the metastatic profile of the Ewing sarcoma 
tumor variants by macroscopic examination of organs isolated by 
dissection followed by histological staining and immunohistochem-
istry. The majority of dissected lungs had macroscopically visible 
metastatic lesions. Lungs derived from mice injected with cells ex-
pressing α5 integrin either alone or with zyxin were extensively rid-
dled with lesions at an elevated frequency (Figure 5C). Stained sec-
tions of lung tissue displayed small, round, blue cells that were 
positive for the Ewing sarcoma marker CD99 (Figure 5C). When dis-
sected bones and organs of mice were examined for presence of 
metastasis by luciferase imaging, mice across all four groups showed 
presence of bone metastasis in addition to lung metastasis (Figure 
5D). Common sites for presence of bone metastasis were uninjected 
leg, upper limb, spine, and ribs, recapitulating what occurs in hu-
man patients.
Reexpression of adhesion proteins in Ewing sarcoma cells 
increases the cellular adherence to lung parenchyma in vivo
To test whether the increased adhesion of Ewing sarcoma cells reex-
pressing zyxin and/or α5 integrin could explain the enhanced inci-
dence of detectable metastatic lung lesions in our mouse experi-
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occurs when the expression of the trans-
forming oncogene itself is compromised by 
RNAi (Chaturvedi et al., 2012). Thus our 
findings identify central aspects of the 
mechanism by which morphological trans-
formation is achieved by the EWS/FLI 
oncogene.
Reexpression of α5 integrin in the small, 
round Ewing sarcoma cells enhances cell 
adhesion as measured in a short-term (2-h) 
quantitative cell adhesion assay. Expression 
of α5 integrin results in a statistically signifi-
cant increase in focal adhesion size relative 
to control cells, as well as enhanced cell 
spreading as assayed by cell area measure-
ments, and correlates morphological 
changes with the elevated retention of cells 
when plated on fibronectin. Expression of 
FIGURE 5: Ewing sarcoma cells that express 
zyxin and α5 integrin metastasize to lungs 
and bones. (A) Metastasis-free survival curve 
of mice evaluated by in vivo luciferase 
imaging of the four cell-type groups at 
weekly intervals. Metastasis was defined as 
appearance of bioluminescence signal other 
than at injection site, primarily the chest area. 
In unpaired t tests between the empty vector 
group and the α5 integrin group, p = 0.0018, 
and between the empty vector group and 
the α5 integrin plus zyxin group, p = 0.0028. 
(B) Week 4 endpoint images of in vivo 
luciferase signal were examined for 
metastasis. Almost all mice injected with 
Ewing sarcoma cells that expressed α5 
integrin, either alone or in combination with 
zyxin, had significant metastasis by in vivo 
imaging, whereas only half the mice injected 
with empty vector control cells or with 
zyxin-expressing cells had in vivo chest signal 
at 4 wk. Dissection of the mice revealed the 
chest signals were due to heavy involvement 
of lungs. **p < 0.01 in unpaired Student’s t 
tests between empty vector group and α5 
integrin alone or α5 integrin plus zyxin group. 
(C) Lungs exhibited macroscopically visible 
lesions (1) that were obvious in every mouse. 
Paraffin-embedded lungs were sectioned, 
and H&E staining identified multiple 
metastases characterized by the presence of 
small, round, blue cells (2, 3). 
Immunohistochemistry for the Ewing sarcoma 
marker CD99 on lung sections (4, brown 
signal) confirmed the presence of Ewing 
sarcoma cells. (D) Immediately after 
dissection, ex vivo luciferase signals of 
multiple organs and skeletal regions were 
examined for each mouse. The number of 
mice positive for luciferase signal in bones, 
lungs, or other organs was scored, and 
results are presented as percentage of mice 
in each group. For all groups of mice, the 
preferred metastatic sites were bones and 
lungs.
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dominant player in the focal adhesion phenotype and α5 integrin 
serving as the dominant influence on cell adhesion.
The development of a high-fidelity orthotopic xenograft model 
for the study of Ewing sarcoma enabled us to explore the influence 
of zyxin and α5 integrin on tumor behavior in vivo. We initially ex-
pected the repression of zyxin and α5 integrin expression that oc-
curs in Ewing sarcoma to provide a consistent “advantage” to the 
tumor cells throughout the tumor’s life history. In accord with that 
view, we found that parental Ewing sarcoma cells with reduced zyxin 
and α5 integrin showed a growth advantage in vivo. In contrast with 
that view, the reduced expression of these two genes adversely af-
fected second-site lung colonization. These contrasting effects on 
the overall “fitness” of the Ewing sarcoma cells at different stages in 
tumor progression provide an example of the kinds of tradeoffs that 
tumor cells make in their evolution (Bernards and Weinberg, 2002).
Exploring these tradeoffs in greater detail, analysis of parental 
Ewing sarcoma cells compared with cells reconstituted with zyxin and 
α5 integrin revealed that the reduction of zyxin and α5 integrin ex-
pression that occurs in Ewing sarcoma cells synergistically promotes 
intratibial tumor expansion in vivo, based on the use of biolumines-
cence imaging as a surrogate means of assessing tumor growth. This 
growth advantage was not recapitulated when cells were grown un-
der two-dimensional culture conditions but was observed in vitro in a 
soft-agar cloning assay that reflects anchorage-independent cell 
growth potential. Of interest, hypoxia has been shown to induce up-
regulation of EWS/FLI expression and a similar enhancement of an-
chorage-independent, but not anchorage-dependent, Ewing sar-
coma cell proliferation (Aryee et al., 2010). The results presented 
here raise the possibility that at least part of the effect of hypoxia on 
Ewing sarcoma growth potential may be attributable to enhanced 
EWS/FLI-dependent repression of zyxin and α5 integrin expression.
Successful growth in soft agar reflects a tumor cell’s resistance to 
anoikis, a form of detachment-induced cell death that limits the abil-
ity of normal cells to survive and grow in an inappropriate environ-
ment (Guadamillas et al., 2011; Kim et al., 2012). Integrin-dependent 
signaling influences anoikis in multiple ways. Whereas integrin 
α5β1 integrin has been shown to promote the acquisition of fibro-
blast-like cell morphology (Truong and Danen, 2009), consistent 
with our findings that the loss of integrin expression appears to play 
a key role in the loss of mesenchymal phenotype that accompanies 
EWS/FLI-dependent transformation (Chaturvedi et al., 2012). Of in-
terest, expression of α5 integrin did not lead to detectable improve-
ment in actin cytoarchitecture and stress fiber integrity, illustrating 
the capacity of integrins to influence cell adhesion even when actin 
cytoarchitecture remains compromised by transformation.
In striking contrast to what is observed when α5 integrin ex-
pression is restored in Ewing sarcoma cells, the reexpression of 
zyxin results in a potent enhancement of actin stress fibers. The 
morphological changes induced in Ewing sarcoma cells by reintro-
duction of a single expression construct highlights zyxin as a mas-
ter regulator of actin cytoarchitecture in these cells. We previously 
demonstrated that zyxin plays a central role in stabilizing and rein-
forcing actin stress fibers in response to mechanical stimulation 
(Yoshigi et al., 2005; Smith et al., 2010). Analysis of fibroblasts de-
rived from mice in which the zyxin gene was disrupted revealed 
that spontaneous, strain-induced actin stress fiber breakage oc-
curred with increased frequency (Smith et al., 2010). The actin cy-
toskeletal deficit in Ewing sarcoma cells may therefore result from 
EWS/FLI-induced repression of zyxin expression that results in fail-
ure of the cytoskeletal repair machinery and unmitigated actin 
damage in the face of mechanical stress. The ability to restore cy-
toarchitecture by simple expression of zyxin also illustrates that 
core elements of the actin assembly machinery remain intact in 
Ewing sarcoma cells.
Reexpression of zyxin in Ewing sarcoma cells also leads to a sig-
nificant increase in the number and size of focal adhesions, high-
lighting the previously described link between actin integrity and 
focal adhesion stability and maturation (Chaturvedi et al., 2012). 
Our quantitative analyses revealed that α5 integrin and zyxin ex-
pression independently influence focal adhesion number/morphol-
ogy and cell adhesion as monitored in a cell plating assay. However, 
the effects are not simply additive, with zyxin appearing to be the 
FIGURE 6: Ewing sarcoma cells that express zyxin and α5 integrin exhibit increased adhesion to lung parenchyma. In 
vivo lung adhesion assay of Ewing sarcoma cells that express empty vector (labeled red, DiI) and cells that express 
zyxin, α5 integrin, or both α5 integrin and zyxin (labeled green, DiO). Red and green cells were combined 1:1, and 
1 million cells were injected into the tail veins of three mice and given 24 h to circulate and adhere. At 24 h, lungs were 
harvested, fixed, and cryosectioned. The numbers of red cell colonies and green cell colonies were evaluated by 
confocal microscopy of lung sections. (A–C) Maximum intensity projection of representative confocal images of lung 
sections, showing red cell colonies (empty vector, yellow arrowheads) vs. green cell colonies (expressing zyxin and/or α5 
integrin, white block arrows) for all groups of mice. Nuclei are stained blue using DAPI. (D) Cell colonies were counted 
for 15 representative sections 4 mm2 in area. Cells expressing zyxin or α5 integrin accumulated more in the lung 
parenchyma compared with empty vector control cells. In addition, cells expressing both zyxin and α5 integrin were the 
most adherent group of cells, with high affinity for lung parenchyma. Graph shows the mean with error bars for SEM. 
Bars identify the data sets compared in unpaired Student’s t tests; *p < 0.05, **p < 0.01, ***p < 0.001.
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importance of tumor microenvironment (Kerbel, 1995; Mundy, 
2002). Prior models established to study Ewing sarcoma metastasis 
typically involved direct inoculation of tumor cells into the vascula-
ture by tail-vein injection (Scotlandi et al., 2000; Hu-Lieskovan et al., 
2005). These models provide insights into the late aspects of meta-
static progression, including extravasation and colonization at sec-
ond sites. Bone injection approaches have been used to study 
Ewing sarcoma biology, including establishment, growth, and oste-
olytic properties in bone and secondary lung metastasis (Guan 
et al., 2005, 2008; Wang et al., 2009; Hauer et al., 2013). We ex-
panded on prior work to develop an orthotopic mouse model of 
Ewing sarcoma that shows spontaneous metastasis from the primary 
bony site to other bones within 4 wk. This intratibial model has been 
used effectively here and by our collaborators to investigate the 
contributions of Ewing sarcoma target genes on tumor growth and 
lung metastasis (Sankar et al., 2013b; Wiles et al., 2013). While our 
manuscript was being reviewed for publication, an intrafemoral 
model of luciferase-tagged Ewing sarcoma cells was reported as a 
system to study tumor cell dissemination to lung, liver/abdomen, 
and other bones, consistent with our findings (Vormoor et al., 2014). 
The ability to manipulate the expression of specific genes in Ewing 
sarcoma cells and study their effect on tumor establishment and 
progression will allow a detailed mechanistic analysis of the roles of 
particular EWS/FLI targets for clinically relevant aspects of tumor 
biology. The preclinical mouse models for Ewing sarcoma that are 
now available should provide a powerful tool to assess mechanisms 
of tumor cell dissemination from the primary bony site and coloniza-
tion at remote sites, as well as provide an improved preclinical envi-
ronment for testing novel therapeutic agents.
MATERIALS AND METHODS
Reagents and antibodies
Antibodies were used for Western immunoblots, indirect immuno-
fluorescence microscopy, and immunohistochemistry as per manu-
facturer’s instructions: paxillin mouse antibody (P13520; Transduc-
tion Laboratories, San Jose, CA), FLI-1 rabbit antibody (15289; 
Abcam, Cambridge, MA), zyxin rabbit antibody (B71; Beckerle Lab), 
α5 integrin (610633; BD Bioscience, San Jose, CA), β-actin AC-74 
mouse antibody and vinculin V9131 mouse antibody (Sigma-Aldrich, 
St. Louis, MO), α-tubulin mouse antibody (12G10; Developmental 
Studies Hybridoma Bank, Iowa City, IA), and CD99 (clone 0-13 
mouse antibody; 620-01; Signet, Cambridge, UK). Secondary anti-
bodies were horseradish peroxidase (HRP)–conjugated antibodies 
for immunoblots (GE Healthcare, Pittsburgh, PA), the Alexa Fluor 
antibodies and phalloidin for microscopy (Molecular Probes/Invitro-
gen, Grand Island, NY), and biotinylated rabbit anti-mouse antibody 
(E0413; Dako, Carpinteria, CA) for immunohistochemistry. Fibronec-
tin to coat coverslips and Mowiol to mount coverslips (Sigma-
Aldrich) and Vybrant Cell-Labeling solutions DiI and DiO (Molecular 
Probes/Invitrogen) were used as per manufacturer’s instructions. 
d-Luciferin (Luck; Gold Biotech, St. Louis, MO) was injected for 
bioluminescence detection. Prolong Gold anti-fade reagent with 
4′,6-diamidino-2-phenylindole (DAPI; P-36931; Invitrogen/Life 
Techno logies) was used for mounting lung sections.
Cell culture
Ewing sarcoma cell lines A673 and EWS502 were grown in DMEM 
with 10% fetal bovine serum (FBS) and RPMI medium with 15% FBS, 
respectively, as previously published (Owen and Lessnick, 2006). 
Selection antibiotics used were puromycin (2 μg/ml; Sigma-Aldrich), 
neomycin (300 μg/ml; Life Technologies), and hygromycin 
(100 μg/ml; Invitrogen).
engagement is normally associated with promoting cell survival, un-
ligated integrins have been shown to induce cell death via mecha-
nisms involving recruitment and activation of specific caspases 
(Stupack et al., 2001; Rajeswari and Pande, 2006). Fibronectin ex-
pression is repressed in Ewing sarcoma cells, and thus a correspond-
ing reduction in α5 integrin expression would be predicted to reduce 
anoikis induced by unligated integrins, facilitating anchorage-inde-
pendent cell growth. Although not yet linked mechanistically to inte-
grin signaling and anoikis, zyxin was identified as a key intracellular 
mediator of apoptosis induced by antibody ligation of the Ewing 
sarcoma marker cell surface protein CD99 (Cerisano et al., 2004). 
Zyxin has also been shown to interact directly with the cell cycle and 
apoptosis regulatory protein CARP-1 (Hervy et al., 2010), providing 
further support for a role for zyxin in apoptotic signaling. The coordi-
nated repression of zyxin and α5 integrin by EWS/FLI could thus pro-
mote survival of Ewing sarcoma cells while simultaneously enabling 
their release from the bone matrix, potentially promoting tumor cell 
dissemination from the primary site (Chaturvedi et al., 2012).
In contrast with the growth and survival advantage achieved in 
Ewing sarcoma cells that is conferred by reduced expression of zyxin 
and α5 integrin, these changes in gene expression were associated 
with compromised ability of the tumors to metastasize to the lung. 
In this situation, the reduced levels of α5 integrin in Ewing sarcoma 
appeared to be primarily responsible for limiting lung metastasis 
compared with tumors in which α5 integrin expression was restored. 
A lung colonization assay in which parental Ewing sarcoma cells or 
cells reconstituted with zyxin and/or α5 integrin were introduced 
into the circulation by tail-vein injection revealed that the cells ex-
pressing the genes were more prominently observed in the lung 
parenchyma, indicating greater success in extravasation and/or ad-
hesion at the second site. Consistent with our findings, a recent 
study of breast, kidney, and bladder tumor cells revealed that α5 
integrin expression facilitates cancer cell adhesion and invasion 
(Mierke et al., 2011). The ability of integrin to influence these prop-
erties was positively correlated with the tumor cells’ ability to trans-
mit and generate contractile forces.
Targeted therapies for Ewing sarcoma are not yet available clini-
cally. Although evaluating the response of cultured Ewing sarcoma 
cells to a novel therapeutic agent is a common early step in drug 
development, the availability of robust animal models for the dis-
ease are essential to facilitate assessment of new agents. High-fidel-
ity mouse models are only available for a limited number of cancer 
types. Many preclinical studies use xenografts in which human tu-
mor cells are injected subcutaneously into immunocompromised 
mice. Although these ectopic xenograft models can be useful, they 
have numerous deficiencies, including the fact that the tumor cells 
do not reside in a microenvironment that is similar to what occurs in 
the patient, and the tumor models often behave very differently 
from what occurs in patients. To overcome this challenge, the devel-
opment of orthotopic xenograft models that faithfully replicate the 
behavior of tumors in patients is a key priority. Recent advances in 
the development of orthotopic xenografts for breast cancer have 
revealed the power of preclinical models for predicting disease out-
come (DeRose et al., 2011; Lum et al., 2012) and create powerful 
tools for preclinical testing of novel therapeutic interventions. Here 
we presented a method for the establishment of orthotopic xeno-
graft models to study Ewing sarcoma. We observed that tumors 
seeded directly into a long bone of the mouse recapitulate oste-
olytic properties that occur in human patients and also metastasize 
to other bony sites in addition to lung. Tumor metastasis in our mouse 
model was not evident in liver or other vital organs, consistent with 
the metastatic profile observed in patients and highlighting the 
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3T5 cell growth assays
These assays were performed three times in duplicate as described in 
Smith et al. (2006). Briefly, 5 × 105 cells were seeded into 10-cm dishes 
for growth in tissue culture and counted every third day to determine 
the rate of cell proliferation and population doubling time.
Soft-agar transformation assays
These assays were performed in duplicate as previously described 
(Lessnick et al., 2002; Chaturvedi et al., 2012). In short, 1 × 105 cells 
were seeded in 0.35% agarose made in Iscove’s modified Eagle’s 
medium, penicillin/streptomycin, and glutamine with or without se-
lection, grown for 3–4 wk, imaged, and colony count noted.
Adhesion assays
These assays were performed at least three times per cell type fol-
lowing previously published protocols (Hoffman et al., 2006; 
Chaturvedi et al., 2012). Ewing sarcoma cells (300,000) were seeded 
in triplicate onto a non–ECM coated 24-well plate for 2 h at 37°C, 
fixed in 3.7% formaldehyde (15 min), stained with 1% toluidene blue 
for 1 h, washed, air dried, and dissolved in 2% SDS. Optical density 
was measured at 620 nm.
In vivo mouse model
All animal protocols were approved by the Institutional Animal Care 
and Use Committee at the University of Utah. Male 5- to 6-wk-old 
NOD/SCID mice (strain code 394; Charles River Labs, Troy, NY) were 
obtained and housed at the University of Utah for 1 wk before ex-
periments. The intratibial tumor injection studies were modified 
from a previously published method (Guan et al., 2008). Mouse tib-
ias were predrilled with a 26-g needle and x-rayed to validate nee-
dle placement; then luciferase-expressing Ewing sarcoma cells 
(2.5 × 105 cells in 10 μl of Matrigel), control A673 cells with empty 
vectors (n = 15 mice), and A673 cells engineered to express zyxin 
(n = 9 mice), α5 integrin (n = 10 mice), or both zyxin and α5 integrin 
together (n = 10 mice) were injected with a glass Hamilton syringe 
and 45o bevel 26-g needle. Tumor growth was monitored weekly for 
4 wk by anesthetizing (isoflurane) the mice, injecting mice intraperi-
toneally with luciferin, and measuring the emitted photons per sec-
ond (Xenogen IVIS 100 Imager and Living Image software, version 
2.50.2; Perkin-Elmer, San Jose, CA). Tumor volume was measured 
with calipers and calculated using the formula 0.5a × b × c, where a, 
b, and c are the three maximum diameters. Consistent with our ani-
mal protocol, mice were killed when tibial tumors measured 2 cm in 
width. Weekly x-rays were recorded (Kodak DXS4000), and oste-
olytic destruction of injected tibias was scored in a blind study by an 
independent analyst (R.L.R.). Bone lysis was graded on a scale of 
0–4, where grade 0 represented no bone loss, grade 1 minimal but 
visible, grade 2 moderate (no cortex affected), grade 3 severe (cor-
tex disrupted), and grade 4 massive bone destruction (Guan et al., 
2008). Before their harvest, mice received a final luciferin injection 
and were killed, the lungs were perfused intratracheally with 4% 
paraformaldehyde, and the bone tumors and lungs were removed, 
imaged for ex vivo luciferase signal, and fixed in neutral buffered 
Formalin. Ex vivo luciferase signal of organs (lung, liver, spleen, kid-
ney, heart, testes, injected tibias, and uninjected bones) was used to 
evaluate other sites of metastasis. Before paraffin embedding, the 
fixed lungs were photographed (whole-lung images) to evaluate 
macroscopically visible lesions.
Immunohistochemical analysis
The fixed bone tumors were decalcified for 7 d before embedding 
in paraffin. The embedded tibias and lungs were sectioned and 
Constructs and retroviruses
Knockdown experiments used the luciferase-RNAi (as control 
RNAi) and EF-2-RNAi (as EWS/FLI RNAi) constructs in pSRP retro-
viral vector with a previously described puromycin resistance 
marker (Smith et al., 2006; Chaturvedi et al., 2012). For expression 
constructs, the human zyxin cDNA was cloned into pMSCV-neo-
mycin retroviral vector (Clontech). The α5 integrin cDNA cloned in 
pMSCV-puromycin retroviral vector was a kind donation from 
Christopher Stipp (University of Iowa, Iowa City, IA). For luciferase 
expression in mice, pMMP-LucNeo or pMMP-LucHygro retrovirus 
was used as previously described (Owen and Lessnick, 2006). 
After retroviral infection for 2 d, cells were selected (puromycin, 
neomycin, or hygromycin) for 2 d before use and maintained for 
up to 5 wk.
Western blots
Whole-cell lysates in RIPA buffer (10 mM Tris-HCl, pH 7, 100 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 
0.1% SDS) with Complete Mini-EDTA-free protease inhibitor cock-
tail tablets (11836153001; Roche Diagnostics GmbH, Indiana-
polis, IN) were electrophoresed (15–30 μg/lane) on 10% SDS–
PAGE gels and transferred onto nitrocellulose membranes. 
Proteins were detected with antibodies for FLI-1 (1:2000), zyxin 
(1:10,000), α5 integrin (1:5000), tubulin (1:10,000), vinculin 
(1:10,000), and HRP-conjugated secondary antibodies, followed 
by Enhanced ChemiLuminescence detection (GE Healthcare).
Immunofluorescence microscopy
The staining, microscopy, imaging, and analysis of fluorescently 
labeled cells were done as previously described (Chaturvedi et al., 
2012). A673 cells (75,000 cells) were plated on fibronectin-coated 
(10 μg/ml) coverslips in 12-well plates for 24 h, fixed in 3.7% form-
aldehyde for 15 min, and permeabilized in 0.2% Triton X-100/
phosphate-buffered saline (PBS) for 5 min. Cells were incubated 
with paxillin antibody (1:100) for 1 h at 37°C, washed (PBS), 
stained with Alexa Fluor anti-mouse antibody (1:200), Alexa 
Fluor–phalloidin (1:100), and DAPI (1:600) for 1 h at 37°C, washed 
(PBS), and mounted in Mowiol medium. Cell images were cap-
tured with a Zeiss Axioskop2 mot plus microscope with a 40× 
objective (numerical aperture [NA] 0.75 NeoFluor), AxioCam 
MR camera, and AxioVision software, version 4.8.1 (Carl Zeiss 
MicroImaging), or with a Nikon A1R Ti inverted microscope, 60× 
oil objective (NA 1.4 Plan Apo DIC N2), and Nikon Elements soft-
ware, version 3.
Cell area, number, and size of focal adhesions
These parameters in Ewing sarcoma cells stained with paxillin an-
tibody and phalloidin were analyzed using immunofluorescence 
images (Nikon A1R Ti inverted microscope with 60× oil objective) 
as previously described (Chaturvedi et al., 2012). Briefly, by use of 
the trace tool the boundaries of phalloidin-stained cells were out-
lined and area of the selected region measured (MetaMorph soft-
ware, version 7.5; Molecular Devices, Sunnyvale, CA). To count 
and measure the size of the paxillin-rich focal adhesions, single-
cell images were first processed (despeckle, remove noise, back-
ground subtraction with rolling ball) in ImageJ (National Institutes 
of Health, Bethesda, MD). Image threshold was set in single-cell 
images, and the area of the thresholded region represented the 
size of focal adhesions (MetaMorph, version 7.5). To measure fo-
cal adhesions using paxillin signal, at least 25 cells were mea-
sured per cell type. To measure cell area, at least 35 cells were 
measured per cell type.
Volume 25 September 15, 2014 Zyxin and α5 integrin in Ewing sarcoma | 2707 
by the National Institutes of Health (R01 GM50877 to M.C.B. and 
R01 CA140394 to S.L.L.), the Huntsman Cancer Foundation, and the 
CureSearch for Children’s Cancer Foundation. The Cancer Center 
Support Grant (2 P30 CA042014) awarded to the Huntsman Cancer 
Institute provided developmental funds and shared resources critical 
to this project.
stained with H&E, or IHC for CD99 (ARUP Laboratories, Salt Lake 
City, UT). The expression of CD99 was detected using clone O-13 
anti-mouse antibody (1:200 dilution) for 2 h at 37°C. Biotinylated 
secondary antibody (1:100) was applied for 32 min at 37°C. Signals 
were detected with a streptavidin-HRP system, using 3-3′ diamin-
obenzidine as the chromogen (Research DAB Detection Kit; Ven-
tana Medical Systems, Tucson, AZ). The slides were counterstained 
with hematoxylin (Ventana Medical Systems) for 8 min, gently 
washed in deionized H2O/Dawn detergent mixture, placed in iodine 
for 30 s, then dipped in sodium thiosulfate, dehydrated in graded 
alcohols (70%, 95% ×2, and 100% ×2), and cleared in xylene; cover-
slips were then mounted (Sheryl Tripp at ARUP and Y.-C.L. at the 
Huntsman Cancer Institute). The tibia and lung sections were evalu-
ated by an independent clinical pathologist (A.G.) in a blind study.
In vivo lung adhesion assay
This assay was done as previously described (Padua et al., 2008; 
Chaturvedi et al. 2012). Briefly, A673 cells with empty vector were 
labeled with Vybrant DiI (red), and A673 cells with expression of 
zyxin, α5 integrin, or both zyxin and α5 integrin were labeled with 
Vybrant DiO (green). The red and green cells were mixed in a 1:1 
ratio, and 1 million cells were injected into the tail vein of NOD/
SCID mice (1303; Jackson Labs) and allowed 24 h to circulate in the 
mouse. Mice were killed after 24 h, and lungs were perfused intra-
tracheally with 4% paraformaldehyde, removed, and cryopreserved 
in OTC freezing medium. Lungs were cryosectioned into 16-μm sec-
tions and examined on a Nikon A1R laser scanning confocal micro-
scope (nine 2-μm optical sections, PlanFluor 40× oil DIC H N2 ob-
jective). A three field by three field (2 mm × 2 mm) mosaic image 
was created (NIS Elements software, version 3) and red versus green 
colonies counted in 15 representative fields from three mice. Two 
such biological replicates were done.
Microarray analysis
Previously published microarray data were reanalyzed for down-
regulated targets of EWS/FLI (Owen et al., 2008). Expression data 
were filtered for a 1.8-fold change across samples, and significant 
changes were identified using permutation testing with a p of 0.01 
after Benjamini and Hochberg correction and significant z-score in 
GeneSifter analysis software.
Statistical analysis
Statistical analysis and graphs were made using Prism 5 software 
(GraphPad, San Diego, CA). The box-and-whisker plots (median 
with 25% quartile above and below in the box; whiskers are mini-
mum to maximum) and mean with SEM are given in the figure leg-
ends. The horizontal line above the graphs identifies the two groups 
compared using unpaired Student’s t tests, which assumed a Gauss-
ian distribution and equal SDs between populations. p < 0.05 in 
unpaired Student’s t tests was considered significant. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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